Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement C1q tumor necrosis factor-related protein 5 (C1QTNF5) is a member of the C1q/tumor necrosis factor (TNF) superfamily that is strongly expressed in retinal pigment epithelium cells. The protein contains a signal peptide, a collagen domain, and a globular C1q-like domain, and it forms both trimeric and higher-order multimeric structures. C1QTNF5 is essential for maintaining retinal structure and function; mutations (notably S163R and others) cause autosomal dominant late-onset retinal degeneration (L-ORD), a disorder characterized by progressive loss of night vision and retinal degeneration appearing in middle age. C1QTNF5 is secreted and may be attached to membranes, playing a role in cell adhesion and interactions within the retinal extracellular matrix. Some functions of C1QTNF5 remain incompletely understood; in mouse, it also regulates adipose tissue browning and autophagy. At present, C1QTNF5 is not established as a direct therapeutic target or receptor, and there are no known drugs that target it directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement C1q tumor necrosis factor-related protein 5 (C1QTNF5).